Science & Medical

10 Hot Tips to Optimize Medical Cannabis Treatments

Medical cannabis is quickly gaining popularity as a viable alternative treatment for a range of ailments. However, as a treatment that is new to most of us, familiarity with its usage is still not as widespread as it should be. To help, we've assembled ten tips from a 2019 research report by Professors Hutchison KE, Hagerty SL, Galinkin J, Bryan AD, and Bidwell LC to help get the most out of it.

In their 2019 Cannabinoids, Pain, and Opioid Use Reduction clinical study on medical cannabis, Professors Hutchison KE, Hagerty SL, Galinkin J, Bryan AD, Bidwell LC give several guidelines for medical cannabis patients and health care providers based on their clinical experience.

Read on for their top ten tips to optimize medical cannabis treatments. But first, don’t forget to download our free cannabis news app.

1) Oral Medical Cannabis Formulations Deliver Minimal Risks

Oral formulations (eg, pill, edible, spray) that contain equal amounts of THC and CBD are likely to have some benefits and minimal risks. (ease of administration, rapid absorption, high bioavailability).

2) Patients Use 3mg of THC per day on Average

Although doses vary widely, medical cannabis patients usually use a dose of 3 mg per day on average. However, a therapeutic benefit and minimal psychoactivity are obtained from 2.5 mg of THC.

3) Work With a Physician Experienced in Medical Cannabis

Patients are advised to work with their physician to increase their medical cannabis does slowly to 2.5 mg of THC or until the desired effect is achieved (i.e. the reduction in pain, reduction in opioid use).

4) Careful Patient Monitoring Is Essential

Careful monitoring is essential with formulations containing THC, as patients may take more than the intended dose. Note that the dosage of CBD can start higher and progress faster because it is not psychoactive, but high doses of CBD will need to be monitored with careful attention of the physician to avoid potential pharmacokinetic interactions.

5) Keep Medical Cannabis Out of Reach of Children

This one goes without saying, but it is also essential that all medical cannabis products are kept well out of the reach of children. They are, after all, medicine.

6) Ensure Medical Cannabis Quality Standards Are Met

Patients should avoid products that have not been manufactured under installations that comply with GMP standards and whose label does not include precise dosage information. Accurate labeling means making use of reputable laboratories.

7) Look Out for Adverse Side Effects

In cases where medical cannabis patients experience adverse cognitive side effects, they should stop using or switch to products containing higher levels of CBD and lower levels of THC.

8) Weigh up the Risks and Benefits of Medical Cannabis

The risks and benefits of medical cannabis use need to be weighed with care in some people, especially for people who: are less than 25 years old, have a significant personal or family history of psychosis are actively being treated for mood disorders/depression, and anxiety or have symptoms of these disorders.

9) Avoid when Pregnant or Breastfeeding

Patients who have certain indications should avoid taking medical cannabis. This includes patients with a current or past cannabis use disorder or other active substance use disorder, cardiovascular or respiratory disease, are pregnant, planning a pregnancy, or breastfeeding.

10) Prefer Non-Inhalation Medical Cannabis Delivery Methods

Although the flowers can be consumed by vaporizers for therapeutic purposes, it is always better to opt for non-inhalation dosage forms such as capsules or oils. Even if there is no combustion, damage to health cannot be excluded with a vaporizer. Moreover, it is not possible to measure the exact dose of active principle consumed.

__

(Featured image by Nataliya Vaitkevich via Pexels)

DISCLAIMER: This article was written by a third-party contributor and does not reflect the opinion of Hemp.im, its management, staff, or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published by Cannabis Sur Ordonnance, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions, or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Desmond O'Flynn

Desmond O’Flynn believes in minimalism and the power of beer. As a young reporter for some of the largest national publications, he has lived in the world of finance and investing for nearly three decades. He has since included world politics and the global economy in his portfolio. He also writes about entrepreneurs and small businesses, as well as innovation in fintech, gambling, and cannabis industries.

Recent Posts

DEA Hearing on Cannabis Reclassification in the United States Postponed to 2025

The DEA has postponed a key hearing on the reclassification of cannabis. The hearing was…

4 hours ago

California Opens Debate on Cannabis Potency With New Report

A new California Department of Public Health report has come out with recommendations for THC…

1 day ago

Ontario Increases Efforts to Combat Illegal Cannabis Market

Ontario is investing $31 million over the next three years to enhance efforts against illegal…

5 days ago

Hanover and Frankfurt Will Be the First German Cities to Legally Sell Cannabis for Adult Use

Frankfurt and Hanover are launching five-year pilot projects for legal, regulated cannabis sales to adults,…

6 days ago

CBD Decree Suspended By Italian Administrative Court for Third Time

Italy's Regional Administrative Court suspended the Health Ministry's decree labeling CBD as a narcotic, pending…

1 week ago

Which U.S. States Will Vote on Cannabis Legalization in November 2024?

This November, five U.S. states will vote on measures related to legalizing recreational or medical…

2 weeks ago